Three Year Study of Insulin Potentiation Therapy in the Treatment of Malignant Neoplastic Diseases | Chapter 15 | Highlights on Medicine and Medical Research Vol. 8

 The use of chemotherapy in the treatment of neoplastic disease still poses various challenges, despite decades of clinical study. Numerous toxicity-related side effects, as well as the possibility of chemoresistance, are significant among the possible complications. Despite the common trend of using a number of new chemotherapeutics in a variety of combinations, progress has been sluggish and unsatisfactory due to the aforementioned factors.

Approach: In search of a fresh perspective, we implemented Insulin Potentiation Therapy (IPT) in our practise. Theoretical foundations and experimental data on insulin's mode of action, as well as its practical implementation, demonstrate that IPT is a promising tool with low toxicity. Furthermore, it allows for a selectively physiological approach to the use of chemotherapy in the treatment of neoplastic disease.

The findings of our three-year experience using Insulin Potentiation Targeted Therapy Low Dose (IPTLD) in the care of 196 patients with a range of neoplastic diseases are presented in this study.

Our findings revealed that patients tolerated IPTLD without difficulty and without experiencing any significant side effects. Our laboratory experiments showed that when chemotherapeutics were used in combination with insulin at a fractionated level in a dose dense regimen, the dose dependent toxicity of the drugs was greatly reduced. Eighty-five of 106 patients (80%) with advanced metastatic disease registered a subjectively meaningful increase in their quality of life after being followed up on.

Conclusions: More extensive experimental evidence and clinical trials are required to gain a better understanding of IPTLD's therapeutic potential. We were able to use IPTLD as a leading tool in the treatment of cancer patients in our practise because of the positive outcomes we obtained and, most significantly, its lower toxicity.

Author (s) Details

Christo Damyanov
Medical Center “Integrative Medicine,” Sofia, Bulgaria.

D. M. Gerasimova
Medical Center “Integrative Medicine,” Sofia, Bulgaria.

L. A. Avramov
Medical Center “Integrative Medicine,” Sofia, Bulgaria.

I. K. Masley
Medical Center “Integrative Medicine,” Sofia, Bulgaria.

Ivan Maslev
Medical Center “Integrative Medicine,” Sofia, Bulgaria.

View Book :- https://stm.bookpi.org/HMMR-V8/article/view/832